Toronto, Ontario – August 17, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has provided a comprehensive corporate update on a recent radio program entitled The Korelin Economics Report. These highlights include: Status of regulatory approval for next generation therapeutic laser Status of sales and marketing team for product launch Revenue expectations post product launch Full interview available here: http://www.kereport.com/2015/08/14/roger-white-update-tlc2000-newest-product-theralase/ Roger Dumoulin-White, President and CEO, Theralase stated, “Theralase is completing the final steps for commercialization of our next generation therapeutic laser as we await Canadian regulatory approval. Post launch, the Company will be in a position to demonstrate the enhanced efficacy that this next generation technology will bring to the worldwide pain market.”   About Theralase Technologies Inc. Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic … Read More

Toronto, Ontario – July 22, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has achieved near complete destruction (~98%) of bladder cancer in an animal model. The Company previously announced on December 9th and 23rd, 2014, respectively, of its success in destroying bladder cancer cells both in a Petri dish and in a preliminary orthotopic rat model in research performed at the University of Toledo. Theralase, in order to optimize the model, relocated it to Princess Margaret Cancer Center, University Health Network (“UHN”) under the direction of Dr. Lothar Lilge, Senior Scientist, UHN and Dr. Arkady Mandel, Chief Scientific Officer (“CSO”) of the Company. Optimization of both the formulation and purity of the lead drug, TLD-1433, by Sigma Aldridge Fine Chemicals (“SAFC”) and the wavelength of laser light used … Read More

Toronto, Ontario – July 17, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser. The TLC-2000 therapeutic laser with patented Cell SensingTM technology, has the unique ability of being able to “sense” injured tissue and then simultaneously deliver a precise dose of laser energy to the area healing it, safer, faster and more effectively than any other competitive product on the market. Theralase expects that this next generation technology will revolutionize the therapeutic laser industry by providing healthcare practitioners with a technology that possesses the repeatability and reproducibility that has been lacking in the field, allowing Theralase the opportunity to catapult for the first time into mainstream medicine. Theralase’s appointment of its new sales and … Read More

Toronto, Ontario – July 16, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed Michael Borovec as the Director of Investor Relations for the Company. Michael possesses over 10 years’ experience in investor relations and capital markets. He successfully completed the Canadian Securities Course, as well as his Series 7, 22 and 63 US licences in 2001. Michael graduated with a Business Management degree from Humber College in 1999 and an International Politics degree from York University in 2005. Roger Dumoulin-White, President and CEO, Theralase stated, “Michael has a strong working knowledge of the financial markets, security regulations and investor relations, with a demonstrated track record in serving as a corporate spokesman in the investor community. Michael’s main role with the organization will be to provide strategic corporate … Read More

Toronto, Ontario – June 18, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the Biotechnology Industry Organization (“BIO”) Conference on Thursday, June 18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 10:30 am ET. About BIO Exhibition: The world’s largest biotechnology gathering, the BIO exhibition allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies. The 2015 BIO exhibition will feature more than 1,700 exhibitors and approximately 160,000 square feet. The exhibition also includes 60+ state, regional and country pavilions who in turn host many companies from their regions. About Theralase Technologies Inc. … Read More

Toronto, Ontario – June 11, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has released commercial versions of its next generation therapeutic laser to its team of Key Opinion Leaders (“KOLs”) and Territory Sales Managers (“TSMs”) for evaluation only purposes. Formal Health Canada approval is expected in early July 2015, allowing commercial sale of the TLC-2000 in Canada. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market. Roger Dumoulin-White, President … Read More

Toronto, Ontario – June 10, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its next generation therapeutic laser, the TLC-2000, has recently received safety approval from the Canadian Standards Association (“CSA”).  CSA conducted an in-depth review of the Company’s technical testing results and approved the product in accordance with the latest international medical standards, including Canadian and US standards. The CSA safety approval paves the way for formal Health Canada approval anticipated in early July 2015. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal … Read More

Toronto, Ontario – May 29, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®), a medical laser company dedicated to commercializing technology to heal pain and destroy cancer, released its first quarter 2015 financial results today, demonstrating an increase of 2% in revenue year over year. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000, with patented Cell SensingTM technology, is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue … Read More

Toronto, Ontario – May 28, 2015 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has granted an aggregate of 4,200,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue. These stock options were granted to directors and officers in compliance with the Company’s 2004 Stock Option Plan approved by the shareholders of the Corporation at the Annual General and Special Meeting held on November 14, 2014. These stock options were granted as a means of rewarding directors and officers for future service to the Corporation, including: Launch of the patented TLC-2000 biofeedback therapeutic laser system with Cell SensingTM technology in 2Q2015 and Commencement of the Health Canada Phase Ib human clinical … Read More

Toronto, Ontario – May 27, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, presented its latest scientific research at the 15th International Photodynamic Association (“IPA”) World Congress in Rio De Janeiro, Brazil from May 22 to 26, 2015. The latest research details the dramatic increase in targeting and efficacy in the destruction of cancer of Theralase’s lead Photo Dynamic Compound (“PDC”) TLD-1433 when bound to transferrin, in a presentation entitled, “Novel biophysical properties of photosensitizer TLD-1433 upon binding to transferrin”   About IPA: The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The purpose of the IPA is to promote the study of diagnosis and treatment using light and … Read More